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ABSTRACT 
Covid-19, an infectious disease caused by coronavirus spreads by salivary droplets or nasal discharge from an infected person during sneezing or 
coughing. This infectious disease is caused by a novel coronavirus, SARS CoV-2 shares the same structure with that of the virus that causes severe 
acute respiratory syndrome (SARS). Most of the people who are infected with Covid-19 will experience respiratory illness and can be treated with 
antiviral drugs and or a combination of antiviral drugs and supportive therapies. Many medical investigational approaches are being investigated to 
design possible treatment strategies and possible avenues for Covid-19 therapy. Potential strategies for the treatment of Covid-19 include antiviral 
medication, the combination of interferons and antiviral drugs, interleukin inhibitors. Recent studies show that the use of plasma from survivors 
can help patients in recovering from the disease. This approach of using plasma is termed as convalescent plasma therapy. Another newer 
technology that includes the construction of a recombinant vaccine is gaining importance for further investigation. The other major approaches 
include the therapeutic use of serine protease inhibitors, chloroquine, hydroxychloroquine, ammonium chloride in definite doses. New study 
approaches include investigation on the production of monoclonal antibodies has gained a way for further clinical research. An effective supportive 
therapy includes extracorporeal membrane oxygenation could be considered as rescued therapy for the patients having respiratory distress. After 
sufficient clinical data is obtained and by taking all these approaches into consideration, the treatment protocol can be designed to treat Covid-19 
successfully. 
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INTRODUCTION 
Coronavirus disease, COVID-19, is an infectious disease caused by a 
coronavirus. Coronaviruses are a large family of enveloped, single-
stranded RNA viruses that infect a broad range of vertebrates. 
Mostly people infected with the COVID-19 virus will experience mild 
to moderate respiratory illness and can be recovered with less 
special treatment. While the elderly people and the people with 
compromised immune systems like cancer and the people with 
underlying medical conditions like cardiovascular disease, diabetes 
and chronic respiratory diseases. 
The COVID-19 virus spreads through salivary droplets or nasal 
discharge from an infected person during sneezing or coughing. The 
better way to prevent or slow down the transmission is by protecting 
oneself from the infection by washing hands or using an alcohol-based 
rub frequently and by not touching the face. It is important to practice 
respiratory etiquette like using a flexed elbow while coughing. 
COVID-19 is the ongoing respiratory disease outbreak and was 
recognized in December 2019 [1]. The novel coronavirus has a structural 
similarity with the virus that causes severe acute respiratory syndrome 
(SARS) and has stood as critical challenge for public health, research and 
medical professionals. Children are less likely to get infected or their 
symptoms were so mild that their infection escaped detection. Many 
medical approaches are being investigated, which include supportive 
therapy along with antiviral medication. Potential developmental 
research of a vaccine is under the process against COVID-19 [2]. Another 
attractive investigational approach includes use of intravenous 
hyperimmune globulin obtained from recovered persons and 
monoclonal antibodies. These approaches need scientific and ethical 
evaluation. By considering the above treatment strategies, the following 
are the possible avenues for COVID-19 therapy. 
Avenues for COVID-19 therapy 
Repurposing old drugs against SARS-CoV occurs to be an interesting 
treatment strategy for the novel coronavirus as it shares a similar 
structure. While focusing on treating viral infection, the treatment 
strategy should include prevention of secondary infections, 
respiratory and circulatory support, and preservation of 
physiological systems, which include renal, hepatic and neurological 
functions. Potential treatment strategies for COVID-19 include:  
Antiviral medication 
As the novel coronavirus has a structural similarity with SARS-CoV, 
the treatment done for SARS-CoV infection could be a possible 
treatment option, which includes a combination of 400 mg ritonavir 
and 100 mg of lopinavir which are potent protease inhibitors used in 
the treatment of human immunodeficiency virus infection. This 
combination was considered for the early treatment of SARS 
patients [3]. The china International Exchange and Promotive 
Association for Medical and Health care (CPAM) has recommended 
the oral administration of lopinavir and ritonavir in combination 
with nebulized alfa-interferon based on retrospective controlled 
studies [4]. 
Korean physicians have developed recommendations for the 
treatment of COVID-19, which include the use of a combination of 
lopinavir and ritonavir or chloroquine in older patients or patients 
with underlying conditions and serious symptoms. However, no use 
of antiviral medication in young, healthy patients with mild 
symptoms and no underlying comorbid conditions is recommended. 
Another nucleoside analogue which is under investigation, 
Remdesivir, has shown significant activity against coronavirus and a 
high genetic barrier to resistance in preclinical trials. Remdesivir has 
shown prophylactic and therapeutic efficacy against 2002 SARS-CoV 
in a mouse model. Hence remdesivir stands out as one of the 
promising treatments for SARS-CoV-2. 
Another promising combination of antiviral medication includes 
Sofosbuvir with ribavirin. The mechanism of action includes the tight 
binding of sofosbuvir and ribavirin to coronavirus RNA dependent 
RNA polymerase. However, much of the clinical data is awaited. 
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Favipiravir, another antiviral drug which is known to inhibit RNA 
viruses is under Phase III clinical trials has gained importance in 
potential possibilities for Covid-19 treatment [5]. 
Antiviral medication with steroids 
Methylprednisolone in the dose of 250 to 500 mg per day for 3 to 6 d 
along with antiviral medication was found to be effective in critically 
ill SARS patients. However, high dose steroids in the absence of an 
effective antimicrobial agent could result in complications related to 
fungal infection and avascular necrosis [3]. 
A prospective observational study of 2002 SARS-CoV infected 
patients who received treatment with ribavirin and corticosteroids 
has shown improvement of initial pulmonary lesions in 45% of 
patients along with possible side effects and no survival benefit [4]. 
Interferon therapy 
There is no enough data on in vitro activity of IFN preparations in 
the treatment of SARS and hence interferon (IFN) is not 
recommended as standard therapy in SARS. 
A combination therapy with ribavirin and interferon (IFN)-α2b has 
shown improved clinical outcomes in MERS-CoV-infected non-
human primates [3]. However, various IFN dosage regimens in 
combination with ribavirin have been given to critically ill patients 
and the possibility for the patients to experience toxicities when the 
drug is given alone or in combination with interferon. Interferons 
can show systemic adverse effects, psychiatric disturbances and 
neutropenia [6].  
A combination of lopinavir/ritonavir and interferon-beta-1b was 
used and the study has shown promising results in the treatment of 
MERS-CoV infection [7]. 
However, use of ribavirin and interferon may be considered if the 
treatment with lopinavir, ritonavir, chloroquine or hydroxyl-
chloroquine are ineffective [4]. 
Another promising treatment strategy includes the use of a 
combination of Interferon alfacon-1 with corticosteroids [8]. 
Interleukin Inhibitors 
Interleukin 6 inhibitors (IL-6) could be suggested as possible 
treatment based on the clinical data of Covid-19 patients, which 
showed increased levels of interleukin 6 in the blood [5].  
As some of the severely affected Covid-19 patients experienced 
hyper inflammation and a ‘cytokine storm’, Interleukin 1 inhibitors 
could be considered as a possible treatment strategy for Covid-19. 
Convalescent plasma therapy  
People who have recovered from the disease have antibodies that 
might help those still suffering from it. The idea of using plasma 
from survivors is known as convalescent-plasma therapy [9]. 
Doctors have transfused the blood of recovered patients into the 
patients with 1918 flu, measles, polio, chickenpox, SARS and Ebola 
and this convalescent plasma therapy has shown varying degrees of 
success. The blood of survivors contains antibodies (proteins) that 
can neutralize the coronavirus has to be pooled and purified to get a 
concentrated dose of antibodies. 
However some evidence recommends the use of plasma antibodies 
early on in the immune response and found to be useful but less 
effective once the patient reaches the stage of organ failure that 
requires hospitalization. The antibodies in the plasma help to 
prevent virus from spreading from the nose and throat into the 
lungs. If these antibodies in plasma can lessen the severity of COVID-
19, this could be one among the key possible treatment strategies. 
Pirofski says if the patients with respiratory symptoms like cough 
and chest pain are administered with antibodies, maybe they won’t 
require supplemental oxygen and intubation.  
Sarilumab (Keyzara) is a fully human monoclonal antibody that 
inhibits the interleukin-6 (IL-6) pathway by binding and blocking 
the IL-6 may render a role in driving the overactive inflammatory 
response in the lungs of critically ill patients with COVID-19. 
Vaccine therapy 
Immunization is achieved using live, attenuated forms of virus or 
part or whole of the virus once it has been inactivated by heat or 
chemicals. As these methods have drawbacks, newer technology has 
gained importance which involves the construction of a 
“recombinant” vaccine. This process involves extracting the genetic 
code for the protein spike on the surface of SARS-CoV-2. As it is the 
part of the virus that provokes an immune reaction in humans, 
genetic code for the protein spike plays a major role in the 
production of vaccine. By incorporating the genetic code of viral 
protein spike into the genome of a bacterium or yeast and then 
making these microorganisms to produce large quantities of the 
protein. Other approaches in developing a vaccine includes 
bypassing the protein and constructing vaccines from the genetic 
information alone. Thus, vaccines for Covid-19 can be constructed 
out of messenger RNA. Using a genetic platform, an investigational 
vaccine is developed based on mRNA [10]. This investigational 
vaccine is supposed to direct the cells in the body to express a viral 
protein, which in turn produces a robust immune response. 
However, different phases of clinical trials are to be carried out on 
the investigational vaccine to get complete safety data.  
Role of serine protease inhibitors  
During SARS CoV-2 virus entry, viral S protein needs to be cleaved 
by cellular proteases at two sites thus, resulting in S protein priming, 
which in turn results in the fusion of viral and cellular membranes. 
S-protein priming happens by TMPRSS2 activity. Hence, inhibiting 
TMPRSS2 activity blocks CoV-2 entry. Thus, serine protease 
inhibitors could be one among the potential avenues for Covid-19 
therapy [11]. Camostat mesylate, a serine protease inhibitor, is 
under clinical trials for its efficacy against Covid-19. 
Role of chloroquine/hydroxychloroquine and ammonium 
chloride in covid-19 therapy  
Chloroquine and hydroxychloroquine are the two medicines currently 
approved to treat malaria and certain autoimmune diseases are under 
investigation for their potential to treat coronavirus disease. Both 
chloroquine and hydroxychloroquine can show serious side effects at 
high doses and when given in combination with other medicines. A 
robust data is being generated based on large clinical trials [12] to 
establish the efficacy and safety of chloroquine and hydroxy 
chloroquine in the treatment of Covid-19. 
Strong antiviral effects on SARS-CoV infected primate cells are 
exhibited by chloroquine when the cells are treated with the drug 
either before or after exposure to the virus. Thus, it suggests both 
prophylactic and therapeutic advantage of the drug, chloroquine. 
Chloroquine is known to elevate endosomal pH and interferes with 
terminal glycosylation of the cellular receptor, angiotensin 
converting enzyme-2 which in turn negatively influences the virus-
receptor binding. Thus, by elevating vesicular pH, infection can be 
inhibited and thus the spread of SARS CoV [13]. 
Role of ammonium chloride in SARS CoV infection-treatment  
Based on the inhibition of SARS-CoV infection by chloroquine when 
added before or after infection, another lysosomotropic agent, 
Ammonium chloride is anticipated to have similar mechanism of 
action. Ammonium chloride is found to reduce the transduction of 
pseudotype viruses having SARS-CoV spike protein. Hence, 
ammonium chloride has gained importance in clinical studies. 
As intra-vesicular acidic pH regulates cellular functions, including N-
glycosylation trimming, cellular trafficking and enzymatic activities, 
it has gained importance to demonstrate the effect of chloroquine 
and ammonium chloride on the cellular processes, glycosylation and 
cellular mechanisms involved in SARS-CoV spike glycoprotein and 
its receptor, Angiotensin-converting enzyme-2. Based on the flow 
cytometry analysis performed on Vero E6 cells which when treated 
with appropriate antiviral concentrations of chloroquine or 
ammonium chloride, it is revealed that drug has not shown any 
significant change in the levels of ACE2 receptors inferring that the 
inhibitory effects on SARS-CoV infection are not because of lack of 
available ACE2 receptors. Based on flow cytometry and 
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immunoprecipitation analyses, it can be concluded that ammonium 
chloride and chloroquine have impaired the terminal glycosylation 
of ACE2 thus making ACE2-SARS-CoV binding less effective 
inhibiting the virus entry. Thus the studies have confirmed that 
elevation of pH caused by chloroquine reduces the transduction of 
SARS-CoV pseudotype viruses. In addition to these studies, 
immunoprecipitation results of ACE2 has shown the effect of anti-
SARS-CoV concentrations of chloroquine and ammonium chloride on 
impairment of terminal glycosylation of ACE2. Based on these 
results, chloroquine treatment prior to infection resulted in 
decreased binding affinities between ACE2 and SARS-CoV spike 
protein and thus negatively influencing the initiation of SARS-CoV 
infection. By considering the analyses, chloroquine and ammonium 
chloride have gained importance in Covid-19 therapy [12]. 
Monoclonal antibodies 
A fully human polyclonal IgG antibody (SAB-301) was found to be 
safe and need further studies for its efficacy to be used in the 
treatment of MERS-CoV infection. As SARS-CoV-2 virus falls under 
same virus family, coronaviridae, the knowledge of this 
investigational monoclonal antibody used to treat MERS-CoV 
infection could be useful in fabrication of monoclonal antibodies 
against SARS-CoV-2 infection. 
According to the study that is published in Science dated April 3, 
2020 from the source, Scripps Research Institute, human antibody’s 
interaction with the new coronavirus at near-atomic resolution is 
mapped. The antibody produced in response to SARS (severe acute 
respiratory syndrome) infection, which is caused by SARS-CoV virus 
has cross-reacted with the new coronavirus, SARS-CoV-2 [14]. Thus, 
the structural mapping revealed a closely identical site on both 
coronaviruses to which the antibody binds, which suggests it as a 
vulnerable site for the family of coronaviruses. These vulnerable 
sites can help in the structure-based design of vaccines and 
therapeutic agents against SARS-CoV-2. Few structural studies of 
antibodies bound to viruses, including HIV and influenza, have been 
carried out and these studies have played a major role in the design 
of vaccines, antibody drugs and other therapeutic agents. 
New study centers have been set up on anti-SARS-CoV antibody 
called CR3022 which was originally isolated in 2006, by the 
pharmaceutical company, Crucell Holland B. V. in Netherlands. From 
the report given by the Chinese scientists earlier this year, shows 
that CR3022 cross-reacts against SARS-CoV-2. The key finding of this 
study using structural mapping includes the information about the 
similarity of antibody’s binding site between the two coronaviruses, 
which differ by just four protein building blocks known as amino-
acids [15]. The Scripps Research analysis concluded that the 
antibody binding site is relatively remote from the part of the virus 
that holds cell-surface protein receptors prior to cellular penetration 
in the lungs. Thus, suggesting that at least for SARS-CoV, CR3002 
neutralizes the ability of viruses to infect cells. These findings 
suggest that the binding site for this antibody on SARS-CoV-2 is a 
site of vulnerability and the antibodies attaching to this site succeed 
in neutralizing the virus. If these neutralizing antibodies are 
developed into therapies, then these antibodies can be considered as 
a potential strategy in the treatment of Covid-19. 
Recombinant human angiotensin-converting enzyme 2 (ACE2) is 
under clinical trials. As SARS-CoV-2 is known to enter cells through 
ACE2 receptor so binding to soluble ACE2 would prevent the virus 
from entering cells [16].  
Hence, certain combination therapies are to be monitored to get 
sufficient clinical data to be used further in treating viral infection. 
Extra corporeal membrane oxygenation  
Extracorporeal membrane oxygenation (ECMO) has been proven to 
be an effective therapy in the treatment of respiratory failure or 
acute respiratory distress syndrome (ARDS) [17].  
From the clinical database of patients with H1N1-related ARDS, it is 
known that ECMO-referred patients have shown lower hospital 
mortality when compared with non-ECMO-referred patients. 
Based on the same mechanism of action, ECMO could pave away in 
the treatment of Covid-19. As per the interim guidance provided by 
World Health Organization (WHO), ECMO should be considered as 
rescue therapy for Covid-19 with refractory hypoxemia despite 
lung-protective ventilation [18]. 
As most of the studies did not report the clinical outcomes of ECMO, 
retrospective studies were conducted by Yang et al. and Guqin et al. 
showed that out of the considerable number of patients who 
received invasive mechanical ventilation (IMV) and ECMO support, a 
very few were benefited by ECMO support. Lack of clinical trial of 
ECMO on Covid-19, it gives incomplete data on the usage of ECMO in 
Covid-19 patients.  
As a few approaches such as intubation [19], ventilator venting and 
sputum suction pose a high risk of infection to medical staff. Hence, 
it is challenging for the medical staff to encounter the pandemic with 
sufficient personal protective equipment. 
CONCLUSION 
The ongoing respiratory disease outbreak, COVID-19 caused by 
novel corona virus, SARS-CoV-2 which has structural similarity with 
the virus that causes severe acute respiratory syndrome (SARS) 
being stood as challenge for public health and medical researchers 
has laid a way for many investigational medical approaches. Though 
a few of the newest approaches need scientific and ethical 
evaluation, keeping into consideration, the possible treatment 
avenues for Covid-19 therapy include antiviral medication 
administered alone or in combination with other antiviral drugs 
and/or steroidal drugs, interferon therapy, interleukin inhibitors, 
convalescent plasma therapy, vaccine therapy, serine protease 
inhibitors, chloroquine or hydroxychloroquine, ammonium chloride, 
monoclonal antibodies. Another approach by which respiratory 
distress associated with corona virus infection can be effectively 
treated by extracorporeal membrane oxygenation for which 
considerable clinical data is to be obtained only of which it could be 
implemented. By considering these methods and by conducting 
research on the potential avenues for Covid-19 therapy, we can get 
complete clinical data of various drugs and treatment strategies that 
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